ASTELLAS PHARMA INC.-COMPANY INSIGHT - TF Market Research

ASTELLAS PHARMA INC.-COMPANY INSIGHT

505 pages — Published Jul 24, 2010
Price $1,495.00  |  Buy this Report Now
  
This report is also available for purchase on a per-page basis.

About This Report

  
Brief Excerpt:
...Comprehensive coverage of ASTELLAS PHARMA INC.'s pipeline of products, including both summary information and detailed individual product records. Publication Date: May ##,#### Life Science Analytics www.lifescienceanalytics.com ### James Avenue Scranton, PA #####...
  
Source:
LIFE SCIENCE ANALYTICS
Author:
LSA
Company
ASTELLAS PHARMA INC
Geographic Regions
ASIA , EASTERN ASIA , JAPAN
Non-Billable Page Numbers
3
Format:
PDF Adobe Acrobat
Sections
TitleStarting PageNumber of Pages
ASTELLAS PHARMA INC.11
Pipeline Report11
ABOUT Life Science Analytics21
Disclaimer21
Business Summary41
Astellas Pharma Inc. [NonUS -- Symbol : Stock Code Number : 4503 (TSE)]41
Formation Date: 200541
Financials51
Product Glance61
Products by Phase of Development Trial Phase61
No. of Products62
Products by Phase of Development Chart61
Products by Disease Hub Classification Disease Hub71
Products by Disease Hub Classification Chart81
Products by Indication Autoimmune and Inflammation Indication91
No. of Products93
Autoimmune and Inflammation Chart91
Blood and Lymphatic System Indication101
Blood and Lymphatic System Chart101
Cancer Indication111
Cancer Chart121
Cardiovascular and Circulatory System Indication131
No. of Products131
Cardiovascular and Circulatory System Chart141
Central Nervous System Indication151
No. of Products151
Central Nervous System Chart161
Dermatology Indication171
No. of Products173
Dermatology Chart171
Digestive System Indication181
Digestive System Chart181
Infections Indication191
Infections Chart201
Kidneys and Genito-Urinary System Indication211
No. of Products218
Kidneys and Genito-Urinary System Chart211
Metabolic/Endocrinology Indication221
Metabolic/Endocrinology Chart221
Miscellaneous Indication231
Miscellaneous Chart231
Musculo-Skeletal-Disorders Indication241
Musculo-Skeletal-Disorders Chart241
Ophthalmology and Optometry Indication251
Ophthalmology and Optometry Chart251
Respiratory and Pulmonary System Indication261
Respiratory and Pulmonary System Chart261
Substance Abuse Indication271
Substance Abuse Chart271
Women's Health Indication281
Women's Health Chart281
Patent Expirations291
Product Active Country Patent Application Name Ingredient Number Number2915
Publication Estimated Date Expiry Date2915
Adenoscan adenosine291
Ambisome amphotericin b Italy Italy301
Amevive alefacept311
ASP1585 bixalomer321
USA USA USA USA USA USA USA Lexiscan regadenoson341
USA USA MDV3100 not available361
Mycamine micafungin sodium361
USA USA USA USA USA USA Prograf tacrolimus Italy391
USA USA USA Vaprisol conivaptan hydrochloride Italy New411
Vesicare solifenacin succinate Italy421
USA USA YM178 mirabegron Austria Brazil Canada China421
Upcoming Milestones441
Date Category Product Name Status Indication441
Milestone441
Company Sales Figures451
Product Name CEFSPAN CEFZON CELECOX CIBENOL DOGMATYL DORNER461
Year Region Qtr 1 Qtr 2 Qtr 3 Qtr 4 Annual461
Product Name Year Region 2005 Japan 2005 Asia 2004 Worldwide 2004 Japan 2004 Asia 2003 Worldwide 2002 Worldwide 2001471
Qtr 1 Qtr 2 Qtr 3 Qtr 4 Annual471
Product Name GASTER GASTER D GENINAX HARNAL HYPOCA INTAL481
Year Region Qtr 1 Qtr 2 Qtr 3 Qtr 4 Annual485
Product Name IRRIBOW LEXISCAN LIPITOR LUVOX MICARDIS MICOMBI MYSLEE491
Product Name NASEA NIVADIL OPTIRAY PERDIPINE501
Product Name PROGRAF PROTOPIC511
Product Name RESCULA SEROQUEL STARSIS SYMBICORT TARGOCID VAPRISOL VESICARE VIBATIV521
Product Pipeline531
Products5318
Condition Treated Trial Source Phase5318
Partner5318
Product Details711
1 . Symbicort Active Ingredient Disease Hub Therapeutic Indication Current Trial Description711
Route of Administration Mechanism of Action712
Mode of Action711
budesonide711
Chemical Structure715
formoterol fumarate dihydrate711
Molecular Weight Molecular Formula Molecule Type Classification724
Trial Details723
Last Updated 2 . MM416775 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description721
linaclotide acetate721
Chemical Name721
Last Updated Partnering Details731
3 . TMX67 Active Ingredient731
Disease Hub Therapeutic Indication Current Trial Description741
Route of Administration Mechanism of Action Mode of Action741
febuxostat741
Chemical Name743
4 . MM416775 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description751
Route of Administration Mechanism of Action751
linaclotide acetate751
Trial Details762
Last Updated Partnering Details763
5 . ASP8825 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description761
Technology Description Route of Administration Mechanism of Action Mode of Action761
gabapentin enacarbil761
Chemical Structure771
Molecular Weight Molecular Formula Molecule Type Classification771
6 . AGS34 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description791
Mechanism of Action Mode of Action Trial Details Last Updated 7 . AGS34 Active Ingredient Product Type Disease Hub791
Therapeutic Indication Current Trial Description801
Description811
Technology Description Mechanism of Action Mode of Action Drug Class811
not applicable811
Molecule Type Classification811
Trial Details Last Updated Partnering Details811
11 . ASG5ME Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description821
Mechanism of Action Mode of Action Trial Details831
Last Updated Partnering Details832
12 . BMS566419 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description851
Mechanism of Action Mode of Action Trial Details851
Technology Description Mechanism of Action Mode of Action862
CD40 monoclonal antibody861
Molecule Type Classification862
Trial Details861
Last Updated Partnering Details871
14 . MAXY4 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description871
not applicable871
Trial Details Last Updated Partnering Details881
15 . AS1949490 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description891
Mechanism of Action Mode of Action Trial Details891
Last Updated 16 . MAXY4 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description891
Technology Description Mechanism of Action Mode of Action901
not applicable901
Molecule Type Classification901
Trial Details Last Updated Partnering Details901
17 . AGS15 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description911
Mechanism of Action Mode of Action Trial Details Last Updated 18 . AGS15 Active Ingredient Product Type911
Disease Hub Therapeutic Indication Current Trial Description921
Mechanism of Action921
Mode of Action Trial Details921
Last Updated 20 . AGS1C4D4 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial931
Description941
Trial Details941
Last Updated Partnering Details941
21 . Vibativ941
Active Ingredient Disease Hub Therapeutic Indication Current Trial Description951
Route of Administration Mechanism of Action Mode of Action951
telavancin hydrochloride951
Chemical Name951
Chemical Structure951
Molecular Weight Molecular Formula Molecule Type Classification951
Trial Details Last Updated 22 . ASP0777 Active Ingredient Disease Hub Therapeutic Indication Current Trial951
Description961
Mechanism of Action961
Molecule Type961
Trial Details961
Last Updated 24 . CTS21166 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description961
Route of Administration Mechanism of Action961
not available961
Last Updated Partnering Details971
25 . ASP3291 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description981
Route of Administration Mechanism of Action Mode of Action981
not available982
Molecule Type982
Trial Details Last Updated 27 . ASKP1240 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description981
Technology Description Route of Administration Mechanism of Action Mode of Action981
CD40 monoclonal antibody981
Molecule Type Classification991
Trial Details Last Updated 28 . ASP2905 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description991
Mechanism of Action991
Trial Details Last Updated 29 . ASP3652 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description991
Description1001
Trial Details1002
Last Updated Partnering Details1001
31 . AGS1C4D4 Active Ingredient Product Type1001
Disease Hub Therapeutic Indication Current Trial Description1011
Last Updated Partnering Details1021
32 . ASP0265 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description1031
Route of Administration Mechanism of Action Mode of Action1031
not available1032
Molecule Type1032
Trial Details Last Updated 33 . FK949E Active Ingredient Disease Hub Therapeutic Indication Current Trial Description1031
Route of Administration Mechanism of Action1031
Mechanism of Action Mode of Action Drug Class Trial Details1042
Last Updated 36 . AGS16M18 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1051
Last Updated 37 . AGS8M4 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1051
Route of Administration Mechanism of Action Mode of Action Trial Details1061
Last Updated 38 . ASP7035 Active Ingredient Disease Hub Therapeutic Indication Current Trial Description1061
Route of Administration Mechanism of Action Mode of Action1063
not available1063
Chemical Name1063
Chemical Structure1074
Molecular Formula Molecule Type1073
Trial Details1075
Last Updated 40 . YM155 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1071
Last Updated 41 . YM155 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1081
Last Updated 42 . ASP8825 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1091
Technology Description Route of Administration Mechanism of Action Mode of Action1091
gabapentin enacarbil1101
Chemical Name1101
Molecular Weight Molecular Formula Molecule Type Classification1101
Last Updated Partnering Details1122
43 . Irribow Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1141
Prescription Route of Administration Mechanism of Action1141
ramosetron1141
Chemical Name1141
Chemical Structure1152
Molecular Weight Molecular Formula Molecule Type Classification1152
Trial Details1153
Last Updated 44 . YM443 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1151
Route of Administration Mechanism of Action1161
Mode of Action1161
acotiamide hydrochloride1161
Chemical Name1161
Last Updated Partnering Details1181
45 . ASP9831 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1181
Description1191
Mechanism of Action Mode of Action Trial Details1191
Last Updated 47 . ASP2151 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1191
Route of Administration Mechanism of Action1191
Mode of Action1201
degarelix acetate1201
Chemical Name1204
Chemical Structure1201
Molecular Formula Molecule Type Classification1201
Trial Details1202
49 . YM155 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial1201
Description1212
Route of Administration Mechanism of Action Mode of Action1211
not available1211
Last Updated 50 . AGS1C4D4 with Gemcitabine Active Ingredient1211
Disease Hub Therapeutic Indication Current Trial1211
Route of Administration Mechanism of Action1221
Mode of Action1221
gemcitabine1221
Molecular Weight Molecular Formula Molecule Type Classification1221
Classification1221
Trial Details1232
Last Updated 51 . Amevive Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1231
Prescription Route of Administration Mechanism of Action Mode of Action Drug Class1231
alefacept1231
Molecular Weight Molecular Formula Molecule Type1231
Classification1241
Last Updated 52 . YM150 Active Ingredient Product Type Disease Hub Therapeutic Indication Current Trial Description1241
Route of Administration Mechanism of Action Mode of Action1241
not available1241

Table Of Contents

TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.

About the Author


Cite this Report

  
MLA:
TF Market Research. "ASTELLAS PHARMA INC.-COMPANY INSIGHT" Jul 24, 2010. Alacra Store. Jun 19, 2013. <http://www.alacrastore.com/storecontent/markintel/LIFE_SCIENCE_ANALYTICS-50395568>
  
APA:
TF Market Research. (2010). ASTELLAS PHARMA INC.-COMPANY INSIGHT Jul 24, 2010. New York, NY: Alacra Store. Retrieved Jun 19, 2013 from <http://www.alacrastore.com/storecontent/markintel/LIFE_SCIENCE_ANALYTICS-50395568>
  
$1,495.00
$  £  €
Have a Question?
Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.
More Research
Search all our Market Research from one place.